Global Neuropsychiatric Drugs Market Size, Share, Growth and Trends Study Report to 2030

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Neuropsychiatric Drugs Market- By Trends, Industry Competition Analysis, Revenue and Forecast to 2030."

Request for Sample Pages:
Neuropsychiatric disorders include a broad range of medical conditions that consist of both neurology and psychiatry. Disturbance in the function of the cerebral system leads to mental disorders. These disorders are majorly observed in children and adolescents. Numerous drugs are available for treating different stages or phases of neuropsychiatric disorders, but most medications have not been tested in children.

The high prevalence of different neuropsychiatric diseases worldwide, growing demand for cost-effective drug treatments, developing pipelines of drugs for neuropsychiatric diseases, increasing innovations of advanced medicines to treat neuropsychiatric disorders, and rising R&D activities to develop novel drugs for treating neuropsychiatric disorders are expected to boost the demand for neuropsychiatric drugs over the forecast period.

Get Free Sample Copy of Report :
https://www.insightaceanalytic.com/request-sample/1170

According to the WHO, depression is one of the leading causes of disability across the world. Globally, around 264 million people are affected by depression. Hence, increasing incidences of such mental disorders are likely to propel market growth opportunities in the upcoming years.
However, long-term treatments and side effects associated with neuropsychiatric drugs such as blurred vision and insomnia may limit the adoption of the market in the coming years.
Geographically, North America is expected to hold the highest share of this market over the forecast years (2020-2030), followed by Europe, owing to the rising mental health awareness, development of the healthcare sector, and increasing R&D investments in developing novel treatments for neuropsychiatric disorders.

Request for ToC/Proposal:
Major market players operating in the neuropsychiatric drugs market include Novartis (Switzerland), Pfizer (US), Otsuka (Japan), Allergan (Ireland), Eli Lilly (US), Sunovion (US), AstraZeneca (UK), Actavis Laboratories (US), Johnson & Johnson (US), Bristol Myers (US), Sage Therapeutics (US), BlackThorn Therapeutics (US), H. Lundbeck A/S (Denmark), Takeda (Japan), Cerevel Therapeutics, LLC (US) among others.
Some of the key developments in the market:
In September 2021, Otsuka Pharmaceutical (Japan) and Sunovion (US), a subsidiary of Sumitomo, collaborated to develop and commercialize four clinical-stage neuropsychiatric compounds (ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614, and SEP-380135). These four compounds are designed to treat psychiatric diseases.
In June 2021, Eli Lilly Alzheimer's drug received breakthrough status from the FDA. The company has plans to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ.
In March 2019, Novartis (Switzerland) received FDA approval for Mayzent (siponimod), the first oral drug to treat relapsing forms of multiple sclerosis (RMS).

Curious about this latest version of the report? Obtain Report Details @
https://www.insightaceanalytic.com/report/global-neuropsychiatric-drugs-market-/1170

Market Segments
Global Neuropsychiatric Drugs Market, by Drug Type, 2020-2030 (Value US$ Mn)
Typical Antipsychotics
oProchlorperazine
oHaloperidol
oOthers
Atypical Antipsychotics
oAripiprazole
oAsenapine
oCariprazine
oClozapine
oLurasidone
oOlanzapine
oRisperidone
oOthers

Global Neuropsychiatric Drugs Market, by Indication, 2020-2030 (Value US$ Mn)
Schizophrenia
Bipolar Disorder
Psychotic Depression
Others

Global Neuropsychiatric Drugs Market, by Route of Administration, 2020-2030 (Value US$ Mn)
Oral
Parenteral

Global Neuropsychiatric Drugs Market, by Region, 2020-2030 (Value US$ Mn)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America Neuropsychiatric Drugs Market, by Country, 2020-2030 (Value US$ Mn)
U.S.
Canada

Europe Neuropsychiatric Drugs Market, by Country, 2020-2030 (Value US$ Mn)
Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Neuropsychiatric Drugs Market, by Country, 2020-2030 (Value US$ Mn)
India
China
Japan
South Korea
Australia & New Zealand

Latin America Neuropsychiatric Drugs Market, by Country, 2020-2030 (Value US$ Mn)
Brazil
Mexico
Rest of Latin America
Middle East & Africa Neuropsychiatric Drugs Market, by Country, 2020-2030 (Value US$ Mn)
GCC Countries
South Africa
Rest of Middle East & Africa

Why should buy this report:
To receive a comprehensive analysis of the prospects for the global neuropsychiatric drugs market
To receive an industry overview and future trends of the neuropsychiatric drugs market
To analyze the neuropsychiatric drugs market drivers and challenges
To get information on the neuropsychiatric drugs market value (US$ Mn) forecast to 2030
Significant investments, mergers & acquisitions in the neuropsychiatric drugs market industry

For More Information @
https://www.insightaceanalytic.com/report/global-neuropsychiatric-drugs-market-/1170

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Corporate Office :
Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com

info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

This release was published on openPR.